BRAF and thyroid gland undifferentiated (anaplastic) carcinoma: In addition, the BRAF inhibitor vemurafenib has been approved for the treatment of patients with Erdheim-Chester disease with BRAF V600 mutations and the combination of dabrafenib and trametinib is approved for treatment of anaplastic thyroid cancer with BRAF V600E mutations.